Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell recovery: a crystal ball for sepsis survival?

NCT ID NCT07787780

Knowledge-focused Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks back at medical records of adults with sepsis in the ICU to see if the way their immune cells (CD4+ and CD8+ T-cells) recover early on is linked to their chances of surviving 28 days. By grouping patients based on these recovery patterns, researchers hope to find clues that help identify who is at higher risk. No treatments are given; it is purely an observational study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify high-risk sepsis patients earlier and tailor monitoring or treatment strategies.
What could go wrong
This is a retrospective observational study, so it cannot prove cause and effect. The findings may not apply to all sepsis patients or lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

303 people

The number who actually took part.

Started

Jan 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult ICU patients with sepsis meeting Sepsis-3.0 criteria, who had at least two serial CD4⁺/CD8⁺ T-lymphocyte subset tests during ICU hospitalization. Retrospective observational cohort from single-center ICU database.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of sepsis according to Sepsis-3.0 criteria (infection plus SOFA score ≥2), admitted to intensive care unit * At least two sequential peripheral blood CD4⁺ and CD8⁺ T-cell absolute count measurements (T1 and T2) during ICU stay * Interval between T1 and T2 \> 3 days Exclusion Criteria: * Age \< 18 years old * Death within 24 hours after ICU admission * Lack of baseline T-lymphocyte subset testing within 72 hours of ICU admission * Receiving glucocorticoid or other immunosuppressive therapy at enrollment * Pregnancy or puerperium status * Critical clinical data missing for analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

Contacts and locations

Locations

  • Sichuan Provincial People's Hospital, Intensive Care Unit

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.